Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.30 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12982442 | 0.94 | OPRM1 (0.37) | RIPK1BDKRB2ADRB2SLC2A1 | |
| SCHEMBL5265204 | 0.92 | SLC2A1 (0.36) | RIPK1SLC2A1DNM1 | |
| SCHEMBL10746726 | 0.92 | SLC2A1 (0.36) | RIPK1SLC2A1DNM1 | |
| SCHEMBL10497055 | 0.89 | BDKRB2 (0.41) | BDKRB2 | |
| SCHEMBL5461974 | 0.87 | RIPK1 (0.36) | RIPK1TAAR1 | |
| SCHEMBL6685021 | 0.84 | RIPK1 (0.40) | RIPK1POLBBDKRB2TAAR1SLC2A1 | |
| SCHEMBL28378978 | 0.82 | RIPK1 (0.33) | RIPK1TAAR1 | |
| SCHEMBL817130 | 0.81 | NR1I2 (0.38) | POLBBDKRB2TSHRSLC2A1DNM1 | |
| SCHEMBL317461 | 0.79 | KDM4E (0.42) | RIPK1POLBBDKRB2ADRB2 | |
| SCHEMBL190051 | 0.78 | RIPK1 (0.55) | RIPK1POLBTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2520570-A1 | AMINOPYRIDINE COMPOUND | Ube Industries, Ltd. (JP) | 2012-11-07 | — | — | EP | claimed |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-10-11 | — | — | US | claimed |
| CN-102666490-A | Aminopyridine compound | UBE INDUSTRIES | 2012-09-12 | — | — | CN | claimed |
| US-RE36128-E | STABILIZER FOR ORGANIC COMPOUNDS | ALBEMARLE CORPORATION (US) | 1999-03-02 | — | — | US | claimed |
| EP-2520570-A1 | AMINOPYRIDINE COMPOUND | Ube Industries, Ltd. (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| CN-102666490-A | Aminopyridine compound | UBE INDUSTRIES | 2012-09-12 | — | — | CN | disclosed |
| EP-2380877-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | Kowa Company, Ltd. (JP) | 2011-10-26 | — | — | EP | disclosed |
| EP-0888262-B1 | CYCLOALKYL DERIVATIVES AND THE SOLID-PHASE SYNTHESIS OF SUCH DERIVATIVES | BASF AG (DE) | 2004-06-02 | — | — | EP | disclosed |
| CN-1140485-C | Cycloalkyl derivatives and solid-phase synthesis thereof | BASF | 2004-03-03 | — | — | CN | disclosed |
| US-6521780-B1 | Cycloalkylmalonic ester derivatives as potential active substances in the drugs and crop protection; combinatorial chemistry | BASF AKTIENGESELLSCHAFT (DE) | 2003-02-18 | — | — | US | disclosed |
| EP-0906324-B1 | CARBOHYDRATE DERIVATIVES AND THEIR SOLID-PHASE SYNTHESIS | BASF AG (DE) | 2001-08-01 | — | — | EP | disclosed |
| US-4900675-A | ENHANCING IMMUNE RESPONSE | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1990-02-13 | — | — | US | disclosed |
| EP-0280938-A1 | Antioxidant aromatic fluorophosphites | ALBEMARLE CORPORATION (US) | 1988-09-07 | — | — | EP | disclosed |
| CN-87103208-A | PHOSPHORAMIDO COMPOUNDS | — | 1988-08-17 | — | — | CN | disclosed |
| US-4746651-A | ANTIBIOTIC AND ALDOGYCOSIDYL-GUANINE OR ISOXANTHOPTERIN IMMUNE RESPONSE-ENHANCING AGENT | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1988-05-24 | — | — | US | disclosed |
| EP-0248084-A4 | MODULATION OF ANIMAL CELLULAR RESPONSES WITH COMPOSITIONS CONTAINING ISOXANTHOPTERIN-8-(1'-BETA-ALDOGLYCOSIDYL) DERIVATIVES. | SCRIPPS CLINIC RES (US) | 1988-03-30 | — | — | EP | disclosed |
| EP-0248084-A1 | MODULATION OF ANIMAL CELLULAR RESPONSES WITH COMPOSITIONS CONTAINING ISOXANTHOPTERIN-8-(1'-BETA-ALDOGLYCOSIDYL) DERIVATIVES. | SCRIPPS CLINIC RES (US) | 1987-12-09 | — | — | EP | disclosed |
| WO-1987003617-A1 | MODULATION OF ANIMAL CELLULAR RESPONSES WITH COMPOSITIONS CONTAINING ISOXANTHOPTERIN-8-(1'-BETA-ALDOGLYCOSIDYL) DERIVATIVES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1987-06-18 | — | — | WO | disclosed |
| US-4103023-A | ANTIULCER, 3,3A,6,6A-TETRAHYDROFURO(3,4-B)FURAN DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | PTGIS, QDPR, PTGIR | RIPK1 4822/4885POLB 2003/4885BDKRB2 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.